VAN DER BURG, SJOERD HENDRIKUS,OTTENHOF, TOM H. M.,GELUK, ANNEMIEKE,SCHOENMAEKERS-WELTERS, MARIA JOHANNA PHILOMENA,DE JONG, ANNEMIEKE M.,OFFRINGA, RIENK,MELIEF, CORNELIS JOHANNES MARIA,TOES, RENE EVER
申请号：
CA2431500
公开号：
CA2431500C
申请日:
2001.12.07
申请国别(地区):
CA
年份:
2016
代理人:
摘要：
The invention is concerned with epitopes derived from human papilloma virus,and peptides having a size of about 22-45 amino acid residues comprisingminimal T cell epitopes. The invention further provides clinically relevantapproaches for immunizing subjects against (Myco)bacterially and/or virallyinfected cells or tumor cells, and in particular against HPV. The inventiondemonstrates that peptide sequences of 22-35 amino acid residues in length caninduce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells.Moreover, the invention demonstrates that vaccination with 22-35 residue longpeptides results in a more vigorous CD8+ cytolytic T-cell response thanvaccination with peptides of the exact minimal CTL epitope length. Theinvention further demonstrates that the intrinsic capacity of certain minimalCTL epitopes which instead of activating cytolytic effector cells tolerizethese cytolytic cells, can be overcome by use of these 22-35 amino acid longpeptides. The invention further provides clinically relevant approaches forvaccination and/or treatment of subjects against HPV. The invention alsoprovides methods and uses suited to treat subjects suffering from progressivelesions and/or cervical cancer.
